KALA BIO, INC. Interest Expense
KALA BIO, INC. (KALA) reported Interest Expense of $1.46 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-14.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-05-14
- KALA BIO, INC. interest expense for the quarter ending 2024-03-31 was $1.46M, a 1.29% decline year-over-year.
- KALA BIO, INC. interest expense for the quarter ending 2023-12-31 was $1.47M, a 6.91% decline year-over-year.
- KALA BIO, INC. interest expense for the quarter ending 2023-09-30 was $1.46M, a 0.83% increase year-over-year.
- KALA BIO, INC. interest expense for the quarter ending 2023-06-30 was $1.41M, a 35.98% decline year-over-year.
- KALA BIO, INC. interest expense for fiscal 2023 was $5.81M, a 19.98% decline from fiscal 2022.
- KALA BIO, INC. interest expense for fiscal 2022 was $7.27M, a 13.29% decline from fiscal 2021.
- KALA BIO, INC. interest expense for fiscal 2021 was $8.38M, a 2.43% decline from fiscal 2020.
- KALA BIO, INC. interest expense for fiscal 2020 was $8.59M, a 1.29% increase from fiscal 2019.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $1.46M 10-Q · filed 2024-05-14 | $2.92M derived: sum of 2 quarters · filed 2024-05-14 | $4.38M derived: sum of 3 quarters · filed 2024-05-14 | $5.79M derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $2.93M derived: sum of 2 quarters · filed 2024-03-29 | $4.34M derived: sum of 3 quarters · filed 2024-03-29 | $5.81M 10-K · filed 2024-03-29 |
| 2023-09-30 | $1.46M 10-Q · filed 2023-11-13 | $2.87M derived: sum of 2 quarters · filed 2023-11-13 | $4.35M 10-Q · filed 2023-11-13 | $5.92M derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-06-30 | $1.41M 10-Q · filed 2023-08-04 | $2.89M 10-Q · filed 2023-08-04 | $4.46M derived: sum of 3 quarters · filed 2024-05-14 | $5.91M derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-03-31 | $1.47M 10-Q · filed 2024-05-14 | $3.05M derived: sum of 2 quarters · filed 2024-05-14 | $4.50M derived: sum of 3 quarters · filed 2024-05-14 | $6.71M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $3.02M derived: sum of 2 quarters · filed 2024-03-29 | $5.23M derived: sum of 3 quarters · filed 2024-03-29 | $7.27M 10-K · filed 2024-03-29 |
| 2022-09-30 | $1.45M 10-Q · filed 2023-11-13 | $3.65M derived: sum of 2 quarters · filed 2023-11-13 | $5.69M 10-Q · filed 2023-11-13 | $7.76M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $2.21M 10-Q · filed 2023-08-04 | $4.24M 10-Q · filed 2023-08-04 | $6.32M derived: sum of 3 quarters · filed 2023-08-04 | $8.39M derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | $2.04M 10-Q · filed 2023-05-09 | $4.11M derived: sum of 2 quarters · filed 2023-05-09 | $6.18M derived: sum of 3 quarters · filed 2023-05-09 | $8.27M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $2.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $4.15M derived: sum of 2 quarters · filed 2023-03-03 | $6.24M derived: sum of 3 quarters · filed 2023-03-03 | $8.38M 10-K · filed 2023-03-03 |
| 2021-09-30 | $2.07M 10-Q · filed 2022-11-08 | $4.16M derived: sum of 2 quarters · filed 2022-11-08 | $6.30M 10-Q · filed 2022-11-08 | $8.47M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $2.09M 10-Q · filed 2022-08-11 | $4.23M 10-Q · filed 2022-08-11 | $6.40M derived: sum of 3 quarters · filed 2022-08-11 | $8.56M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $2.14M 10-Q · filed 2022-05-16 | $4.31M derived: sum of 2 quarters · filed 2022-05-16 | $6.47M derived: sum of 3 quarters · filed 2022-05-16 | $8.60M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $2.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $4.33M derived: sum of 2 quarters · filed 2022-03-29 | $6.46M derived: sum of 3 quarters · filed 2022-03-29 | $8.59M 10-K · filed 2022-03-29 |
| 2020-09-30 | $2.16M 10-Q · filed 2021-11-15 | $4.29M derived: sum of 2 quarters · filed 2021-11-15 | $6.42M 10-Q · filed 2021-11-15 | $8.56M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $2.13M 10-Q · filed 2021-08-05 | $4.26M 10-Q · filed 2021-08-05 | $6.41M derived: sum of 3 quarters · filed 2021-08-05 | $8.59M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $2.13M 10-Q · filed 2021-05-05 | $4.27M derived: sum of 2 quarters · filed 2021-05-05 | $6.45M derived: sum of 3 quarters · filed 2021-05-05 | $8.51M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | $2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $4.33M derived: sum of 2 quarters · filed 2021-02-25 | $6.39M derived: sum of 3 quarters · filed 2021-02-25 | $8.48M 10-K · filed 2021-02-25 |
| 2019-09-30 | $2.18M 10-Q · filed 2020-11-05 | $4.24M derived: sum of 2 quarters · filed 2020-11-05 | $6.33M 10-Q · filed 2020-11-05 | $8.44M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $2.06M 10-Q · filed 2020-08-06 | $4.16M 10-Q · filed 2020-08-06 | $6.25M derived: sum of 3 quarters · filed 2020-08-06 | $6.69M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $2.09M 10-Q · filed 2020-05-07 | $4.19M derived: sum of 2 quarters · filed 2020-05-07 | $4.63M derived: sum of 3 quarters · filed 2020-05-07 | $5.04M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | $2.53M derived: sum of 2 quarters · filed 2020-02-12 | $2.95M derived: sum of 3 quarters · filed 2020-02-12 | $3.31M 10-K · filed 2020-02-12 |
| 2018-09-30 | $432.00K 10-Q · filed 2019-11-07 | $846.00K derived: sum of 2 quarters · filed 2019-11-07 | $1.21M 10-Q · filed 2019-11-07 | $1.61M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $414.00K 10-Q · filed 2019-08-06 | $781.00K 10-Q · filed 2019-08-06 | $1.18M derived: sum of 3 quarters · filed 2019-08-06 | $1.39M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | $367.00K 10-Q · filed 2019-05-09 | $768.00K derived: sum of 2 quarters · filed 2019-05-09 | $980.00K derived: sum of 3 quarters · filed 2019-05-09 | $1.19M derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $401.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $613.00K derived: sum of 2 quarters · filed 2019-03-12 | $821.00K derived: sum of 3 quarters · filed 2019-03-12 | $1.02M 10-K · filed 2019-03-12 |
| 2017-09-30 | $212.00K 10-Q · filed 2018-11-08 | $420.00K derived: sum of 2 quarters · filed 2018-11-08 | $618.00K 10-Q · filed 2018-11-08 | $819.00K derived: sum of 4 quarters · filed 2018-11-08 |
| 2017-06-30 | $208.00K 10-Q · filed 2018-08-09 | $406.00K 10-Q · filed 2018-08-09 | $607.00K derived: sum of 3 quarters · filed 2018-08-09 | $793.00K derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | $198.00K 10-Q · filed 2018-05-10 | $399.00K derived: sum of 2 quarters · filed 2018-05-10 | $585.00K derived: sum of 3 quarters · filed 2018-05-10 | $771.00K derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | $201.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $387.00K derived: sum of 2 quarters · filed 2018-04-02 | $573.00K derived: sum of 3 quarters · filed 2018-04-02 | $767.00K 10-K · filed 2018-04-02 |
| 2016-09-30 | $186.00K 10-Q · filed 2017-11-07 | $372.00K derived: sum of 2 quarters · filed 2017-11-07 | $566.00K 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $186.00K 10-Q · filed 2017-08-31 | $380.00K 10-Q · filed 2017-08-31 | ||
| 2015-12-31 | $604.00K 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |